<DOC>
	<DOCNO>NCT00906698</DOCNO>
	<brief_summary>To determine maximum tolerate dose , safety , pharmacokinetics anti-tumour efficacy oral BIBW 2992 combination intravenous oral vinorelbine</brief_summary>
	<brief_title>Afatinib Vinorelbine Tumours Known Overexpress EGFR and/or HER2</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis malignancy advance , non resectable and/or metastatic Tumours historically know overexpress EGFR and/or HER2 Exclusion criterion : Prior treatment HER2 inhibiting drug within past 4 week start therapy concomitantly trial . Prior treatment EGFR inhibiting drug within past two week start therapy concomitantly trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>